IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-62509-z.html
   My bibliography  Save this article

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial

Author

Listed:
  • Paolo Strati

    (The University of Texas MD Anderson Cancer Center)

  • Lei Feng

    (The University of Texas MD Anderson Cancer Center)

  • Jason R. Westin

    (The University of Texas MD Anderson Cancer Center)

  • Ranjit Nair

    (The University of Texas MD Anderson Cancer Center)

  • Luis E. Fayad

    (The University of Texas MD Anderson Cancer Center)

  • Maria A. Rodriguez

    (The University of Texas MD Anderson Cancer Center)

  • Dai Chihara

    (The University of Texas MD Anderson Cancer Center)

  • Luis Malpica

    (The University of Texas MD Anderson Cancer Center)

  • Jared Henderson

    (The University of Texas MD Anderson Cancer Center)

  • Mariana Gallardo

    (The University of Texas MD Anderson Cancer Center)

  • Marissa Rivera

    (The University of Texas MD Anderson Cancer Center)

  • Iris Wang

    (BostonGene, Corp)

  • Anastasiia Bolshakova

    (BostonGene, Corp)

  • Anastasia Radko

    (BostonGene, Corp)

  • David Kurtz

    (Foresight Diagnostics Inc)

  • Stefan K. Alig

    (Ludwig-Maximilian-University (LMU) Hospital)

  • Christopher R. Flowers

    (The University of Texas MD Anderson Cancer Center)

  • Ash A. Alizadeh

    (Stanford University School of Medicine)

  • Sattva S. Neelapu

    (The University of Texas MD Anderson Cancer Center)

Abstract

This phase II trial aims to determine the efficacy and safety of frontline acalabrutinib, lenalidomide and rituximab for patients with advanced stage follicular lymphoma (FL) and high tumor burden. The primary endpoint was best complete response (CR) rate; the secondary endpoints were overall response rate (ORR), duration of response measured as CR at 30 months (CR30), progression of disease at 24 months (POD24) rate, progression-free survival (PFS), overall survival and safety. Twenty-four patients with previously untreated FL were included in this phase 2 single arm study (NCT04404088). The most common grade 3-4 adverse events were neutropenia (58%) and liver function test elevation (17%). Best ORR was 100% and best CR rate was 92%. CR30 rate was 65% and POD24 rate was 17%. After a median follow-up of 43 months, median PFS and OS were not reached, 2-year PFS rate was 79% and 2-year OS rate was 92%. Here we show that the addition of acalabrutinib to R2 is a safe and effective frontline regimen for FL patients, and further exploration in larger clinical trials is needed.

Suggested Citation

  • Paolo Strati & Lei Feng & Jason R. Westin & Ranjit Nair & Luis E. Fayad & Maria A. Rodriguez & Dai Chihara & Luis Malpica & Jared Henderson & Mariana Gallardo & Marissa Rivera & Iris Wang & Anastasiia, 2025. "Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial," Nature Communications, Nature, vol. 16(1), pages 1-10, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62509-z
    DOI: 10.1038/s41467-025-62509-z
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-62509-z
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-025-62509-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62509-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.